Venturis Therapeutics

Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.

Utilizes human proteins from the Fibroblast Growth Factor (FGF) family to stimulate therapeutic angiogenesis (growth of new blood vessels) for treating ischemic conditions.

Venturis competes in the therapeutic angiogenesis space, which includes other growth factor-based approaches (e.g., VEGF), cell therapies, and gene therapies. In diabetic wounds, competitors range from advanced wound care companies to regenerative medicine firms. In cardiovascular ischemia, competition includes large pharma and medical device companies offering revascularization procedures.